Gene: KEL

3792
CD238|ECE3
Kell metallo-endopeptidase (Kell blood group)
protein-coding
7q34
Ensembl:ENSG00000197993 MIM:613883 Vega:OTTHUMG00000157159 UniprotKB:P23276
NG_007492.2
PubMed
0   ANCO-SNPs
CD|ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.936e-1 (AD)  6.864e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TRPV50.864
ASPA0.835
SH3TC20.831
ZFP570.828
ST180.827
DYSF0.824
GAB20.814
BTBD160.811
VRK20.809
CTNNA30.808

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CALB2-0.517
CUX2-0.47
SLC29A4-0.446
TAC3-0.438
CHRNA2-0.431
PCDH8-0.428
NEUROD1-0.425
DLX5-0.416
VIP-0.413
NGB-0.413

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB02557PhosphoramidonSmall Molecule36357-77-4ExperimentalTarget
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KEL mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KEL mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KEL mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KEL mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KEL mRNA"25510870
D000082AcetaminophenAcetaminophen affects the expression of KEL mRNA17562736
D020106AcrylamideAcrylamide results in decreased expression of KEL mRNA28959563
C547126AZM551248AZM551248 results in decreased expression of KEL mRNA22323515
C006780bisphenol Abisphenol A results in decreased expression of KEL mRNA25181051
D003300Copper[Copper co-treated with Dietary Sucrose] results in increased expression of KEL mRNA26033743
D003300CopperCopper deficiency results in increased expression of KEL mRNA26033743
D003471CuprizoneCuprizone results in increased expression of KEL mRNA26577399
D004041Dietary FatsDietary Fats results in decreased expression of KEL mRNA25016146
D019422Dietary Sucrose[Copper co-treated with Dietary Sucrose] results in increased expression of KEL mRNA26033743
D019422Dietary SucroseDietary Sucrose results in increased expression of KEL mRNA26033743
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of KEL mRNA23649840
D005557FormaldehydeFormaldehyde results in increased expression of KEL mRNA23649840
C069837fullerene C60fullerene C60 results in decreased expression of KEL mRNA19167457
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of KEL mRNA23649840
C017096n-butoxyethanoln-butoxyethanol results in increased expression of KEL mRNA19812364
C028007nickel monoxidenickel monoxide results in decreased expression of KEL mRNA19167457
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of KEL mRNA25729387
C030110oxaliplatinoxaliplatin results in decreased expression of KEL mRNA25729387
D010269ParaquatParaquat results in increased expression of KEL mRNA15458575
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of KEL mRNA"25510870
C008890phosphoramidonKEL protein alternative form binds to and affects the metabolism of phosphoramidon15769748
D011192Potassium DichromatePotassium Dichromate results in increased expression of KEL mRNA23608068
D011441PropylthiouracilPropylthiouracil results in decreased expression of KEL mRNA24780913
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of KEL mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of KEL mRNA19465110
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of KEL mRNA25729387
D019772TopotecanTopotecan results in decreased expression of KEL mRNA25729387
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of KEL gene25560391
D014752Vinyl ChlorideVinyl Chloride results in increased expression of KEL mRNA18579281
C016837zinc chloridezinc chloride results in increased expression of KEL mRNA16973896

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004222metalloendopeptidase activity-IDA15769748  
GO:0005515protein binding-IPI7737196  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006508proteolysis-IEA-  
GO:0006874cellular calcium ion homeostasis-IEA-  
GO:0008361regulation of cell size-IEA-  
GO:0010961cellular magnesium ion homeostasis-IEA-  
GO:0031133regulation of axon diameter-IEA-  
GO:0042310vasoconstriction-TAS15769748  
GO:0042552myelination-IEA-  
GO:0048741skeletal muscle fiber development-IEA-  
GO:1901380negative regulation of potassium ion transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0016021integral component of membrane-TAS9647734  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-373076Class A/1 (Rhodopsin-like receptors)TAS
R-HSA-375276Peptide ligand-binding receptorsTAS
R-HSA-500792GPCR ligand bindingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25524052Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. (2015 May)Cohen-Barak OJ Clin Pharmacol